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CASE REPORT
Primary intestinal aspergillosis resulting in acute intestinal volvulus after
autologous stem cell transplantation in a patient with relapsed non-Hodgkin
lymphoma: report on a rare infectious complication and a review of the
literature
Soetkin Kennese, Dirk Van de Puttea, Jo Van Dorpeb, Vanessa Van Hendec, Tessa Kerred
and Philip Vlummens d
aDepartment of Gastro-Intestinal Surgery, Ghent University Hospital, Ghent, Belgium; bDepartment of Pathology, Ghent University
Hospital, Ghent, Belgium; cDepartment of hematology, AZ Nikolaas, Sint-Niklaas, Belgium; dDepartment of Hematology, Ghent
University Hospital, Ghent, Belgium; eDepartment of Hematology, Ghent University Hospital, Ghent, Belgium
ABSTRACT
Objectives: Since primary intestinal aspergillosis is a severe infectious complication with a
high morbidity and mortality in immunocompromised patients, we want to draw attention to
this rare entity and the importance of early recognition.
Methods: We report a case of documented primary intestinal aspergillosis in a patient
receiving an autologous stem cell transplantation (SCT). Furthermore, this article gives a
short reﬂection on the occurrence of invasive aspergillosis in autologous SCT and the value
of serum galactomannan levels based on literature search and linked with the case.
Results: In this case the patient presented on day +8 after autologous SCT for a relapsed
diﬀuse large B-cell lymphoma with an acute abdomen with urgent need for surgical inter-
vention. Biopsy revealed the presence of fungal colonies due to aspergillosis and voriconazole
was started. Until that day the systematically taken serum galactomannan tests were all
negative or pending. Initially there was some resistance to perform surgery in the presence
of neutropenia and thrombocytopenia but in the end it provided the deﬁnitive diagnosis and
should not be delayed. Until now this patient is in good health and retains a complete
remission.
Conclusion: With this case, we would like to emphasize that early recognition of primary
intestinal aspergillosis is of the utmost importance as it is a rare but serious infectious
complication. It should be included in the diﬀerential diagnosis of neutropenic patients







A 21-year-old man was admitted for an autologous stem
cell transplantation (SCT) as consolidation therapy for
relapsed diﬀuse large B-cell non-Hodgkin lymphoma of
the nasopharyngeal cavity. Before the autologous trans-
plant complete remission was obtained using salvage
chemotherapy consisting of three cycles of rituximab
(375 mg/m2), dexametasone (50 mg), high-dose ara-C
(2 × 2000 mg/m2) and cisplatin (100 mg/m2) (R-DHAP).
Peripheral autologous stem cells were collected after the
second cycle of R-DHAP following granulocyte-macro-
phage colony-stimulating factor mobilization for
10 days. A high-resolution CT of the lungs and sinuses,
performed as part of his pre-transplant workup, was
normal (Figure 1(a)). The conditioning regimen was the
standard BEAM-protocol (BiCNU/carmustine 300 mg/m2,
etoposide 200 mg/m2 and cytarabine 200 mg/m2 twice
daily for 4 days and melphalan 140 mg/m2). No apparent
complications were seen during conditioning and stem
cell reinfusion but on day +3 the patient developed
neutropenic fever for which broad-spectrum antibiotics
(piperacilline/tazobactam 4 × 4g intravenous (IV)) were
administered empirically. All cultures remained negative.
White blood cell engraftment was reached on day +8 and
was complicated by severe acute abdominal pain. CT
imaging of the abdomen revealed obstruction of the
small intestine (Figure 1(b)). The development of an
acute abdominal syndrome with hemodynamic instabil-
ity prompted an emergency laparotomy on day +8 show-
ing volvulus involving the proximal jejunum with
imminent perforation (Figure 1(c)). Repositioning and
decompression was performed with creation of a tem-
porary jejunostomy. Biopsies taken during the procedure
revealed the diagnosis of an invasive mycosis, the
branching of the hyphae was compatible with aspergil-
losis (anatomopathology, Figure 1(d, and e)), but no
fungal culture or PCR was performed. After starting IV
voriconazole (6 mg/kg loading dose, followed by 4 mg/
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kgmaintenance) alongside conventional supportive ther-
apy, infectious parameters decreased slowly. Galacto
mannan assays were systematically performed twice
weekly during aplasia. The ﬁrst positive sample was
taken at day +7 (6,2), but was only known at day +11
and therefore after the surgical exploration. The deﬁnitive
diagnosis of invasive aspergillosis was established by the
combination of histopathology and a positive galacto-
mannan test. After 7 days in the intensive care unit, the
patient could be transferred back to the haematology
ward. Persistent bleeding of the fragile intestinal mucosa
was suspected due to a drop in haemoglobin and con-
ﬁrmed by CT angiography. Arterial embolization was
performed at day + 21 and repeated at day + 34.
Resection of the involved intestinal segment however,
could be avoided.
A high-resolution CT of the lungs performed at day
+ 42 because of recurrent fever and coughing showed a
lesion compatible with invasive pulmonary aspergillosis
(Figure 1(f)), new compared to pre-transplant imaging
(Figure 1(a)). As such, the diagnosis of a primary intest-
inal aspergillosis with secondary haematogenic spread
to the lungs was assumed. Until this day there were no
respiratory symptoms present.
Due to hepatotoxicity (total bilirubin 6.3 mg/dL, AST
112 U/L, ALT 99 U/L, yGT 887 U/L, alkaline phosphatase
482 U/L), voriconazole was temporarily switched to IV
caspofungin (70 mg loading dose at the ﬁrst day, fol-
lowed by 50 mg once daily in maintenance). This was
not related to toxic drug levels of voriconazole, ranging
from 1,5 to 4,6 mg/L during treatment. After improve-
ment of the liver enzymes, voriconazole could be
Figure 1. (a): Screening HRCT pre-SCT excluding pulmonary aspergillosis. (b): Contrast-enhanced CT abdomen showing marked
dilatation of the small bowel alongside stranding of fatty tissues. (c): Surgical exploration showing volvulus of the proximal
jejunum with imminent perforation. (d): Microscopy of the surgical specimen showing completely necrotic mucosa (Mu) and
submucosa (SM) with numerous aspergillus hyphae. Haematoxylin and eosin staining, original magniﬁcation ×200. MM:
muscularis mucosae. (e): High magniﬁcation showing acutely branching and septate aspergillus hyphae. Grocott’s methenamine
silver staining, original magniﬁcation ×400. (f): Post-surgery HRCT showing presence of a multinodular lesion (tree-in-bud sign)
with surrounding ground-glass inﬁltrates, suggestive of peri-lesional haemorrhage. As such, secondary pulmonary aspergillosis
was suspected.
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restarted at 250 mg twice daily per os. In total, this
patient received antifungal therapy for 3 months, then
therapy could be stopped considering the clinical, bio-
chemical and radiographical resolution.
During the long period of revalidation that fol-
lowed this severe complication, the patient suﬀered
from cytomegalovirus reactivation for which consecu-
tively gancyclovir and valgancyclovir were started. He
also developed high ﬂuid output of the jejunostomy,
probably due to persistent inﬂammation of the intest-
inal lining. IV ﬂuid replacement was needed alongside
octreotide therapy. On day +99, a control colono-
scopy showed the development of signiﬁcant disuse
colitis. As suﬃcient healing of the proximal jejunum
was present, intestinal re-anastomosis was performed
on day +102, completely alleviating high ﬂuid output.
At his latest evaluation in February 2018 (more
than 3 year after transplantation), the patient still
remains in a complete remission and is in excellent
general condition.
Discussion
The incidence of invasive aspergillosis in autologous
SCT ranges from 2% to 6% (mean 4,8%) with a very
high mortality (78–92%) [1]. The most recent pub-
lished mortality rates in autologous SCT patients do
however date from 15 years ago [1]. As mortality
rates, associated with invasive aspergillosis, have
declined over the past decade in haematology
patients in general, prognosis in autologous SCT
patients could also already be improved due to better
supportive care and antifungal treatment [2,3].
Unfortunately, no up-to-date data concerning this
patient population has been published recently.
Invasive aspergillosis is most commonly seen in the
respiratory tract and when present in the gastrointest-
inal tract, it is mostly in the context of disseminated
disease. Besides inhalation, aspergillus spores can also
be ingested, although primary intestinal aspergillosis
is rare and the incidence is estimated around 1% of
fungal infections. It may be underreported because of
the diﬃcult diagnosis which can sometimes only be
made by autopsy, this presumptive underestimation is
supported by the higher number of cases found in
autopsy series [4,5].
Here, we described a case of primary gastrointest-
inal aspergillosis in which involvement of the lungs
probably only developed afterwards, it was presented
as an acute abdomen as early as day +9. In the
literature we found a mean time to onset of 20 days
after autologous SCT [1]. The incidence of primary
gastrointestinal aspergillosis in the setting of autolo-
gous SCT cannot be found in literature, but few case
reports were published [4,5]. Most of the reported
patients with primary gastrointestinal aspergillosis
have received an allogeneic SCT or high dose
chemotherapy for acute myeloid leukaemia. In the
setting of autologous SCT invasive aspergillosis in
general and certainly primary gastrointestinal asper-
gillosis is much more rare, partly due to the shorter
neutropenic period and a less immunocompromised
state.
After ingestion, aspergillus spores cannot invade the
intact mucosal barrier. In a SCT setting, however, like in
the presented case, there are predisposing factors com-
promising the mucosal barrier such as neutropenia
resulting in increased bacterial translocation or aggra-
vating existing colitis, mucosal toxicity due to che-
motherapy and use of steroids and/or broad spectrum
antibiotics [2,6–9].
In contrast to the more commonly aﬀected site of
sino-pulmonary aspergillosis with clear symptoms and
typical imaging, gastrointestinal disease is more diﬃ-
cult to detect and to prove. Radiological ﬁndings in
gastrointestinal aspergillosis may vary from character-
istic thickening of the bowel wall to an image of sub-
obstruction with colon distension [10], as in this case,
CT scan showed an obstruction of the small intestine.
Furthermore a positive serum galactomannan in
patients without evidence for respiratory involvement
on CT scan is often considered as a false positive
result. But some of them may be ‘true positive’ results
localized at unusual sites of aspergillosis infection
such as gastrointestinal and should prompt a more
thorough search for aspergillus in other organs [11].
On the other hand, in a retrospective analysis by
Kazan et al., galactomannan antigenaemia testing in
proven gastrointestinal aspergillosis was only positive
in 16 out of 25 patients (64%), including four of eight
cases of isolated gut aspergillosis (50%). The frequency
of performing the galactomannan assay was not men-
tioned [12]. A meta-analysis of Pfeiﬀer et al. found a
sensitivity of 0.71 and a speciﬁcity of 0.89 for the
galactomannan antigen test in general, when per-
formed in haematological patients in speciﬁc they
found a sensitivity of 0.70 and a higher speciﬁcity of
0.92. For those receiving a transplantation, the sensi-
tivity was higher (0.82), but the speciﬁcity was lower
(0.84) [13]. The serum galactomannan assay has a high
speciﬁcity in neutropenic patients and the reproduci-
bility is best in patients with a high pretest probability,
so it should be used in this context [13,14]. In our
centre, we only routinously perform serum galacto-
mannan testing during the aplastic episode, as per-
formed in the presented case. Two of the four cases
of primary gastrointestinal aspergillosis with a false
negative galactomannan test result in the retrospective
analysis by Kazan were performed on non-neutropenic
patients, which can explain the low sensitivity [12].
Marr et al. analysed the galactomannan assay in
patients with proven aspergillosis and they could not
ﬁnd a positive test result in those without neutropenia;
on the contrary 80% of the neutropenic patients did
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have a positive galactomannan. They suggested that
non-neutropenic patients develop less extrapulmonary
dissemination resulting in a reduced sensitivity [15].
In several series of case reports, gastrointestinal
involvement required tissue preservation by sur-
gery to conﬁrm the diagnosis due to aspeciﬁc
symptoms, imaging ﬁndings and negative serum
galactomannan [6,12]. However, surgery of neutro-
penic patients is generally avoided whenever pos-
sible, leading to underdiagnosis of gastrointestinal
aspergillosis. Our patient presented with an acute
abdomen without any respiratory symptoms or
other evidence of a primary respiratory localization,
requiring urgent laparoscopic intervention. The
result of the serum galactomannan, performed
biweekly as part of the standard monitoring during
the neutropenic period, was not readily available
when the decision to perform surgery was made
and only came back positive after acute branching
aspergillus hyphae were seen on the surgical
biopsy specimen. The ﬁnding that the lesion was
transmucosal can attribute to the argument that
the aspergillosis was primary gastrointestinal.
There are no clear recommendations for the man-
agement of gastrointestinal aspergillosis available. A
successful two-step approach in surgery – with ﬁrst
resection and decompression with construction of a
stoma and re-anastomosis after recovery – is
described in case reports [16]. Commonly, a combi-
nation of medical and surgical treatment is needed
[12]. Surgery makes an opportunity to reduce fungal
burden and to resolve complications as the obstruc-
tion in our presented case [12]. Prolonged exposure
to speciﬁc antifungals is advised for the treatment
of documented infections, with a minimum of 6–
12 weeks. Although exact duration of therapy is
not well deﬁned, it need to be continued until
clinical, antigenemic and radiographic normalization
and as long as the patient remains under immuno-
suppresion [17].
Primary intestinal aspergillosis is generally asso-
ciated with a very poor prognosis and results in a
high risk for disseminated disease, partly due to late
diagnosis. In a case series, 53% of the haematological
patients survived at 3 months. Patients who under-
went surgery had a slightly higher chance of survival
(41.7%) compared to those who did not (33.3%) [12].
Our patient urgently underwent a laparoscopy with
the construction of a temporary jejunostomy, in addi-
tion he received antifungal therapy for 3 months and
until this day he remains in good health and in com-
plete remission.
Conclusion
Intestinal aspergillus is rare and associated with high
mortality. It should therefore be included in the
diﬀerential diagnosis of neutropenic patients with sud-
den onset abdominal pain and ongoing fever, certainly
when a positive galactomannan is seen in the absence
of sino-pulmonary symptoms/lesions. Also, our case
illustrates that a pending serum galactomannan test
result, even in the presence of prior negative results,
should not delay surgical exploration as an acute pri-
mary intestinal aspergillosis cannot be ruled out.
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